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Preoperative cardiac evaluation does not improve
or predict perioperative or late survival in
asymptomatic diabetic patients undergoing
elective infrainguinal arterial reconstruction
Thomas S. Monahan, MD, Gautam V. Shrikhande, MD, Frank B. Pomposelli, Jr, MD, John J. Skillman,
MD, David R. Campbell, MD, Sherry D. Scovell, MD, Frank W. Logerfo, MD, and Allen D. Hamdan,
MD, Boston, Mass
Objective: Patients undergoing infrainguinal arterial reconstruction frequently have increased cardiac risk factors.
Diabetic patients are often asymptomatic despite advanced cardiac disease. This study investigates whether preoperative
cardiac testing improves the outcome in diabetic patients at risk for cardiac disease.
Methods: We retrospectively reviewed all patients undergoing lower-extremity arterial reconstructions in a 32-month
period from July 1999 to February 2002. Of the 433 patients identified undergoing 539 procedures, 295 had diabetes
mellitus and considered in this study. The patients were stratified into two groups according to the present American
College of Cardiology, American Heart Association (ACC/AHA) algorithm. We identified 140 patients with two or
more of ACC (Eagle) criteria who met the inclusion criteria for a preoperative cardiac evaluation. These patients were
separated into two groups: those undergoing a cardiac work-up (WU) according to the ACC/AHA algorithm and those
not undergoing the recommended work-up (NWU). Outcomes included perioperative mortality, postoperative myocar-
dial infarction, congestive heart failure, arrhythmia, and length of hospitalization. Significance of association was assessed
by the Fisher exact test. Length of hospitalization was compared using the Kruskal-Wallis rank sum test. Survival data was
analyzed with the Kaplan-Meier method.
Results:One hundred forty patients met the criteria for moderate risk. There were 61 patients in the NWU group and 79
in the WU group. Ten patients in the WU group underwent preoperative coronary revascularization (6 had percutaneous
transluminal coronary angioplasty, 4 underwent coronary artery bypass grafting). There was no difference between
perioperative mortality (WU, 1%; NWU, 2%; P  1.00) or in postoperative cardiac morbidity, including myocardial
infarction, congestive heart failure, and arrhythmia requiring treatment (WU, 5%; NWU, 6%; P  .71). There were no
perioperative deaths and one episode of congestive heart failure in the group that had preoperative coronary revascular-
ization. Median length of hospitalization was 10 days in the WU group and 8 days in the NWU group (P .11). Patient
survival at 12 months for the NWU, WU, and revascularized groups was 85.3%, 78.5%, and 80.0%, respectively;
36-month survival was 73.6%, 62.9%, and 80.0%, respectively. The three survival curves did not differ significantly (P 
.209).
Conclusions: Preoperative cardiac evaluation, as defined by the ACC/AHA algorithm, does not predict or improve
postoperative morbidity, mortality, or 36-month survival in asymptomatic, diabetic patients undergoing elective
lower-extremity arterial reconstruction. These data do not support the current ACC/AHA recommendations as a
standard of care for diabetic patients with an intermediate clinical predictor who undergo peripheral arterial reconstruc-
tion, a high-risk surgical procedure. (J Vasc Surg 2005;41:38-45.)Peripheral artery disease (PAD) is a manifestation of
systemic atherosclerotic disease. The presence of PAD in-
creases the all-cause mortality rate by threefold and the
cardiovascular mortality rate by nearly sixfold.1 Patients
with diabetes mellitus have a greater incidence of PAD than
nondiabetic patients. The incidence of coronary artery dis-
ease and stroke is increased in diabetic patients compared
with age and sex-matched nondiabetic patients.2 Patients
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38with diabetes mellitus also have a higher mortality from
coronary heart disease than nondiabetic patients.3 On the
basis of these data, patients with diabetes mellitus who
undergo revascularization procedures for PAD are theoret-
ically at increased risk for adverse cardiac events.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) recognize the theoret-
ical increased risk for adverse cardiac events in diabetic
patients undergoing vascular surgery. ACC and AHA have
published extensive algorithms to risk-stratify patients hav-
ing noncardiac surgery (Fig 1).4,5 Peripheral vascular pro-
cedures are considered high-risk procedures by the ACC/
AHA guidelines. Step 6 of the ACC/AHA algorithm
recommends that patients undergoing a high surgical-risk
procedure with an “intermediate clinical predictor” such as
diabetes have a cardiac evaluation. According to the present
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Volume 41, Number 1 Monahan et al 39Fig 1. The American College of Cardiology/American Heart Association algorithm for perioperative cardiovascular
evaluation for noncardiac surgery. *Subsequent care may include cancellation or delay. CHF, congestive heart failure;
ECG, electrocardiogram METS, metabolic equivalents of oxygen consumption; MI, myocardial infarction. Reprinted
from ACC/AHA Guidelines for the Perioperative Cardiovascular Evaluation for Noncardiac Surgery. J Am Coll
Cardiol 1996;27:910-48. Copyright 1996 The American College of Cardiology Foundation and American Heart Associ-
ation. Permission granted for one time use. Further reproduction is not permitted without permission of the ACC/AHA.
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preoperative cardiac evaluation prior to an infrainguinal
arterial reconstruction.
Although it is obviously desirable to limit cardiac mor-
bidity in patients having peripheral vascular procedures, it is
not clear that a preoperative cardiac evaluation is effective
to this end. No prospective randomized trial has been
performed to assess the benefit of a preoperative cardiac
evaluation, and only one randomized controlled trial has
been initiated to evaluate the benefit of prophylactic coro-
nary revascularization compared with best medical manage-
ment.6
The present study is a retrospective review of patients who
had elective infrainguinal arterial reconstruction procedures.
For the purpose of this study, we only considered asymptom-
atic patients. Also, we eliminated patients who required an
emergent operation because the cardiac evaluation was often
deferred owing to the life-threatening circumstances. We se-
lected a group of patients with diabetes mellitus and PAD who
were at high risk for cardiac morbidity and thus should show
the greatest benefit from a cardiac evaluation.
METHODS
In compliance with the standards of the Institutional
Review Board, we retrospectively reviewed the medical
records of 433 consecutive patients undergoing 539 in-
frainguinal arterial reconstruction procedures at the Beth
Israel Deaconess Medical Center during the 32-month
period from July 1999 to February 2002. Data were pro-
spectively entered into a computerized vascular registry.
Additionally, electronic medical records and all clinic notes
were reviewed retrospectively. For patients with multiple
operations, only the index operation during this time pe-
riod was considered. All procedures were performed by staff
vascular surgeons, assisted by a vascular fellow or a general
surgery resident. Patients routinely recovered in a vascular
step-down unit before being transferred to the patient
floor.
Only patients who had elective arterial reconstructions
were considered in this study (step 1). Any patient with a
major clinical predictor as defined by the ACC/AHA algo-
rithm, including myocardial infarction (MI) within 1
month, unstable angina, decompensated congestive heart
failure (CHF), severe valvular disease, or significant ar-
rhythmias, was not included in this study because, accord-
ing to the algorithm, they warranted a cardiac evaluation on
the merit of their cardiac symptoms (step 4). Patients who
received cardiac revascularization, including coronary ar-
tery bypass grafting (CABG) and percutaneous translumi-
nal coronary angioplasty (PTCA), with or without stenting,
within 5 years of their index operation outside of the
context of a preoperative work-up were also excluded as
they should not receive further cardiac evaluation accord-
ing to the algorithm (step 2).
Peripheral vascular procedures are considered “high
surgical-risk procedures” by the ACC/AHA guidelines.
Patients with two or more of the Eagle criteria (age  70,
diabetes, angina, q wave on preoperative electrocardiogram[ECG], ventricular arrhythmia, and history of CHF) were
considered to have an “intermediate clinical predictor.7
Patients with an intermediate clinical predictor who require
a high surgical risk procedure are recommended to have a
preoperative cardiac evaluation. These patients were sepa-
rated into two groups: those undergoing a cardiac work-up
(WU) according to the ACC/AHA algorithm and those
not undergoing the recommended work-up (NWU).
The Eagle criteria were used in place of intermediate
clinical predictors in the present study. This substitution
was made because the Eagle criteria encompass the inter-
mediate clinical predictors; they are more stringent and less
subjective. The criteria for diabetes, CHF, and angina are
the same for both systems.
The Eagle criteria substitute q wave on preoperative
ECG for past MI. This is a significant change, because only
patients with documented, ECG evidence of past MI were
considered to have an indication for cardiac evaluation.
This eliminates the patients who might have had an MI of
lesser clinical significance, such as a transient elevation of
cardiac enzymes noted incidentally.
The Eagle criteria also include age greater than 70; this
is a “minor clinical predictor” according to the ACC/AHA
guidelines. Patients with peripheral vascular disease have
poor functional capacity due to their disease process and
their cardiac capacity is difficult to assess. Cardiac evalua-
tion is also recommended for patients with a minor clinical
predictor, poor functional status, and who are scheduled to
have a high-risk procedure (steps 7 and 8).
A patient who underwent any diagnostic test designed
to elicit ischemia or delineate anatomic defects in the
coronary circulation was considered to have had a cardiac
evaluation. These tests include stress ECG, stress echocar-
diography, stress tomoscintigraphy, and cardiac catheter-
ization. All patients in both cohorts had a resting ECG
performed as a component of the standard preoperative
testing.
Demographic data and preoperative risk factors in our
patient population, including age, hypertension, previous
MI, CHF, serum creatinine level, and diabetes mellitus,
were entered prospectively. The presence or absence of a Q
wave on ECG and length of hospitalization were deter-
mined by retrospective chart review. Postoperative compli-
cations including MI and CHF requiring treatment were
identified at clinical assessment and entered prospectively
into the registry by staff, fellows, or residents.
The routine cycling of cardiac enzymes and postoper-
ative ECG for asymptomatic patients are not part of the
patient-care protocol. An ECG was only obtained if symp-
toms, including nausea, or a clinically significant change in
hemodynamic parameters were present. Arrhythmia requir-
ing treatment was also determined on retrospective chart
review.
MI, CHF, and arrhythmia together were considered a
combined cardiac morbidity endpoint. Perioperative mor-
tality included fatality from any etiology within 30 days of
the operation. Date of death was determined from both the
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chart review. The cause of death was not always identified.
Statistical analysis was performed with STATA software
(version 8.0, Stata Corporation, College Station, Tex). The
association between perioperative mortality, cardiac mor-
bidity, and cardiac evaluation was assessed using the Fisher
exact test. Significance was considered for P values less than
.05. Length of hospitalization was assessed using the
Kruskal-Wallis rank sum test and associations were consid-
ered significant for P values less than .05. Survival analysis
was performed with the Kaplan-Meier method and values
were considered significant at P less than .05 (Cox-Mantel
log-rank test).
RESULTS
We reviewed the records of 433 consecutive patients
undergoing 539 infrainguinal arterial reconstructions, 259
of whom had diabetes mellitus. Of these patients, we
identified 140 who had elective procedures, had not had a
coronary revascularization procedure within 5 years, and
met the ACC/AHA criteria for preoperative cardiac evalu-
ation. Seventy-nine of these patients had the recommended
preoperative cardiac evaluation (WU) and 61 did not have
an evaluation (NWU).
In the WU cohort, 48 nuclear stress tests, 15 stress
echocardiographs, and 5 ECG stress tests were performed.
Eleven patients were directly referred for cardiac catheter-
ization without a stress test. Preoperative evaluation re-
sulted in cardiac catheterization in 19 patients. As a result of
the preoperative cardiac work-up, 6 patients had PTCA
preoperatively and 4 patients had a CABG procedure prior
to their peripheral vascular reconstruction. The decision to
pursue coronary revascularization was at the discretion of
the cardiologist performing the procedure.
The NWU and WU groups were similar in proportion
of men (72% and 72% respectively, P  .96), average age
(72 and 71 years, P  .67), median serum creatinine level
(1.2 and 1.0 mg/dL, P .78), proportion on dialysis (11%
and 16%, P .40), proportion with a history of CHF (31%
and 46%, P .083), and number of Eagle criteria (2.5 and
2.7, P  .15). The WU group had significantly more
patients with a prior MI (62% vs 44%, P  0.036). Patient
demographics are listed in Table I. All procedures were
performed by five surgeons (Table II), with equal represen-
tation in each group (P  .117).
Perioperative cardiac morbidity and mortality was com-
parable in each cohort (Table III). Four patients in the
NWU (7%) and WU (5%) cohorts had a postoperative MI,
clinically significant CHF, or arrhythmia requiring treat-
ment (P  0.71). Postoperative mortality was similar in
each group, with only one postoperative death in each
cohort (NWU, 2%; WU, 1%; P  1.00).
Length of hospitalization was measured from the time
of admission to the hospital to the time of discharge.
Length of stay ranged from 2 to 38 days (median 8) in the
NWU cohort and 4 to 48 (median 10) in the WU group (P
 .11).Patient survival at 1 year was 85.3% and 78.5% for the
NWU and the WU cohorts (Fig 2); survival at 36 months
was 73.6% and 62.9%. Survival was significantly higher in
the NWU cohort by Kaplan-Meier analysis (P  .044).
Survival for the 10-patient cohort that had coronary revas-
cularization subsequent to cardiac evaluation was 80% at
both 12 and 36 months. Both patients who died in the
revascularized group had had a PTCA prior to their periph-
eral vascular procedure. There was no difference in this
survival curve from the WU or NWU survival curves (P 
.209).
DISCUSSION
In the present study, we identified 140 asymptomatic
diabetic patients undergoing elective infrainguinal arterial
reconstruction. These patients met the established ACC/
AHA criteria for preoperative cardiac evaluation. On retro-
spective review, 79 patients had a cardiac evaluation as
would be recommended by the ACC/AHA and 61 patients
Table I. Patient demographic data
No work-up Work-up P
Demographics
Total patients 61 79
Male gender 44 (72%) 50 (73%) .96
Eagle criteria 2.5 (0.8) 2.7 (0.8) .15
Procedures performed
Distal bypass 45 (74%) 62 (78%)
Proximal bypass 16 (26%) 17 (22%) .52
Intermediate clinical
predictors
Angina 4 (7%) 11 (14%) .16
Prior MI† 27 (44%) 49 (62%) .036*
CHF 19 (31%) 36 (46%) .083
Diabetes 61 (100%) 79 (100%) 1.0
Renal insufficiency‡ 8 (13%) 19 (24%) .10
Dialysis dependent 7 (11%) 13 (16%) .40
Creatinine (mg/dL) 1.2 (1-1.8) 1.0 (0.7-9.3) .78
Minor clinical predictors
Age (years) 71.9 (10.1) 71.1 (11.1) .67
Hypertension 44 (72%) 63 (80%) .29
History of stroke 4 (7%) 17 (22%) .014*
MI, Myocardial infarction; CHF, congestive heart failure.
*Denotes statistical significance.
†Prior myocardial infarction is defined either by patient history or patholog-
ical Q waves on preoperative electrocardiogram.
‡Renal insufficiency is defined as a baseline serum creatinine level  2
mg/dL.
Table II. Patients receiving a preoperative cardiac
evaluation by surgeon
Work-up No work-up
Surgeon A 19 25
Surgeon B 14 4
Surgeon C 13 7
Surgeon D 27 19
Surgeon E 6 6
79 61did not.
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perioperative mortality, perioperative cardiac morbidity, or
late survival. The incidence of perioperative MI in this series
is 1.4% for all patients, 1.6% for NWU patients, and 1.3%
for WU patients. These data compare favorably with other
cited rates of MI after infrainguinal bypass procedures.8,9
Despite this, patients in this series had a slightly higher
incidence of postoperative adverse cardiac events than pre-
viously cited in our institution.10 This increase in incidence
likely reflects a selection bias; this series only considered
patients with two or more Eagle criteria.
Cardiac evaluation is not a benign procedure. At best, it
delays time to operation and incurs a significant cost to the
healthcare system. Additionally, a positive stress test fre-
quently prompts a cardiac catheterization to localize ana-
tomic defects in the coronary circulation. Cardiac catheter-
ization is an invasive procedure that carries many risks.
Angiography requires the administration of contrast mate-
rial to patients who frequently have tenuous renal function.
A 1% incidence of AV fistulae resulting from the groin
puncture has been documented in the cardiology litera-
ture.11 Other less-common complications, including ne-
crotizing fasciitis, have also been documented.12 If a defect
is identified at cardiac catheterization, patients with PAD
have greater morbidity and mortality rates associated with
PTCA and CABG procedures than do patients without
PAD.13,14
Screening stress tests, including exercise ECG stress
test, stress echocardiography, and nuclear perfusion stud-
ies, are designed to identify hemodynamically significant
lesions. However, primary MIs in ambulatory patients are
most likely caused by stenoses of less than 50%. The likeli-
hood of plaque rupture, thrombosis, and resulting MI is
more closely related to the architecture and stability of the
atherosclerotic plaque than the degree of stenosis that the
plaque causes.15 Current screening tests often fail to iden-
Table III. Postoperative mortality (a) and cardiac
morbidity (b)*
a No work-up Work-up P
No postoperative 60 78
mortality
Postoperative 1 (2%) 1 (1%) 1.00
Mortality
b No work-up Work-up P
No postoperative 57 75
morbidity





MI, Myocardial infarction; CHF, congestive heart failure.
*Cardiac morbidity is presented both as a cumulative endpoint and as the
incidence of the individual endpoints.tify the plaques that are most likely to cause MI. An autopsyseries demonstrated a poor correlation between ischemic
regions identified on stress echocardiography and the loca-
tion of infarction.16
Nuclear imaging studies have been evaluated for their
efficacy in predicting adverse cardiac outcomes. One series
of more than 200 patients cites a sensitivity of 38% and
specificity of 63% for the prediction of adverse cardiac
outcomes.17 Back and colleagues18 evaluated the efficacy of
cardiac stress imaging compared with angiography in pre-
dicting adverse cardiac outcomes. They demonstrated that
three-vessel disease was an independent predictor of cardiac
morbidity, whereas nuclear imaging failed to predict ad-
verse outcomes.18
In addition to the potential complications associated
with catheterization and the debatable reliability of nonin-
vasive cardiac examinations, asymptomatic patients who are
referred for cardiac evaluation might be deterred from
having the indicated peripheral vascular procedure. The
patients in this study were culled from our computerized
vascular registry, which only collects data on patients who
have had a vascular procedure. Patients who had a preop-
erative cardiac evaluation and did not have an infrainguinal
reconstruction were not included in the present study.
Based on an adverse cardiac evaluation, these patients
might have been encouraged to have an amputation instead
of the planned vascular reconstruction.
Alternatively, patients might have decided against fur-
ther procedures after a long cardiac work-up. This is not an
uncommon scenario; a series from a Veterans Administra-
tion (VA) hospital reports that as many as one fifth of
patients deferred vascular surgery after a preoperative car-
diac evaluation, despite potentially life-threatening abdom-
inal aortic aneurysms.19
Finally, cardiac catheterization is not a benign proce-
dure and is associated with some mortality. Obviously these
patients were not included in the present study. Although
there is a selection bias in the present study, it is conceivable
that if all patients referred for cardiac evaluation were
included in the analysis, the WU group would, in fact, have
had more adverse outcomes than the NWU group.
The present study has several limitations. It is a retro-
spective study with the selection bias and reporting bias
inherent in all retrospective studies. We identified patients
whose comorbidities warranted a preoperative cardiac eval-
uation. These patients did or did not have the recom-
mended evaluation, generally at the discretion of a consult-
ing cardiologist. There was no randomization, and
consequently, the two groups were not homogeneous. A
significantly higher percentage of patients in the WU co-
hort had had a prior MI.
The number who met our inclusion criteria was rela-
tively small—140 patients. Our evaluation began reviewing
the medical records of 433 patients who had 539 consecu-
tive infrainguinal arterial reconstruction procedures. Be-
cause of the small number of patients considered in this
study, there is a possibility of type II error.
A preoperative cardiac evaluation might improve out-
come either by providing a benefit from coronary revascu-
olid l
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improvement in medical management in the perioperative
period. This improvement is reflected in the increased
incidence of perioperative -blockade in the patients in this
study who had a perioperative cardiac evaluation (59% vs
77%, P  .021).
After analyzing the patient data, we only identified 10
patients who had coronary revascularization as a direct
result of a preoperative cardiac evaluation. These patients
had a 1- and 3-year survival of 80%. This survival curve is
not statistically improved from the survival curve of the
group without a cardiac evaluation. Too few patients had a
revascularization procedure in this series to determine if
such a procedure actually improves late survival.
The patients who had preoperative coronary revascu-
larization had either PTCA or a CABG procedure. It is
important to consider these patients separately when deter-
mining outcomes associated with coronary revasculariza-
tion. The method of revascularization is not of trivial
concern. Presently, no prospective, randomized controlled
trials have been published that demonstrate improvement
in survival after coronary angioplasty in asymptomatic pa-
tients. The data from the VA trial comparing prophylactic
coronary revascularization to best medical management
will demonstrate whether or not angioplasty improves sur-
vival in asymptomatic patients.6
It is well demonstrated that diabetes mellitus is a risk
factor for MI and the other sequelae of atherosclerotic
disease. However, diabetes mellitus as a risk factor for
untoward perioperative events has been challenged. In
more than 6,500 vascular procedures performed at our
institution, diabetes was not associated with an increase in
Fig 2. Kaplan-Meier analysis for patients with and w
represents the cohort that had a cardiac evaluation, the smortality or perioperative cardiac morbidity.10Several factors contribute to the low incidence of post-
operative events. In our institution, the surgical service has
adopted a team approach to the care of the vascular patient
and works closely with the cardiology service and endocri-
nologists from the Joslin Diabetes Center. This approach
lends to better medical management, including consistent
perioperative -blockade, antiplatelet regimens, and tight
glycemic control.20 In addition, the frequent use of pulmo-
nary artery catheters and a specialized vascular nursing unit
contribute to improved outcomes.
These data, together with the present study, challenge
the validity of diabetes as an independent risk factor for
adverse perioperative events. Algorithms that use diabetes
mellitus alone as a criterion for a preoperative cardiac
evaluation should be reconsidered.
To better evaluate the benefit or harm caused by sub-
jecting patients to a preoperative cardiac evaluation, a
larger, prospective randomized trial is needed. Such a study
has not been performed. This investigation is among the
largest series evaluating outcome data in patients receiving
a preoperative cardiac evaluation. These data suggest that it
is acceptable to offer patients infrainguinal arterial recon-
struction without an antecedent cardiac evaluation. Be-
cause the ACC guidelines are well accepted, it is ethically
difficult to obtain institutional review board approval to
randomize at-risk patients to no work-up. Studies such as
this should provide the evidence to support the needed,
larger, prospective randomized trials.
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Dr Carlos Donayre (Los Angeles, Calif). Dr Monahan and
colleagues have relied on their extensive experience with diabetic
patients to address the ACC guidelines for preoperative cardiac
evaluation in patients undergoing infrainguinal bypass.
I would like now to address the following: The cardiac evalu-
ation was not uniform in patients undergoing revascularization and
they underwent a variety of stress tests. Eighteen patients under-
went cardiac catheterization. Eleven did so directly without any
preoperative cardiac evaluation. What was the indication for direct
cardiac catheterization?
Secondly, we do almost all of our cases under regional anes-
thesia with beta blockade. Was this your practice, and can this
approach be credited for lowering the mortality and cardiac mor-
bidity in these patients? Lastly, what kind of workup is utilized in
your institution in patients undergoing aortic surgery, which is a
much higher risk group?
I congratulate you on your paper and your presentation, and
I’d like to thank the Society for the privilege to discuss your paper.
Dr Thomas Monahan. First, the indications for cardiac cath-
eterization were highly variable. Generally, the decision to proceed
either directly to catheterization or to catheterization after a non-
invasive workup was at the discretion of the referring cardiologist.
Their practices varied greatly, especially throughout the time
course that we studied.
Second, with respect to selection of anesthesia and periopera-
tive beta-blockade, virtually all of the procedures were performed
under general anesthesia. The issue of beta-blockade really strikes
at the heart of the study. Preoperative cardiac evaluation can
improve patient outcome by two methods: First, it could incite a
more aggressive, more thorough medical management of therevascularization, which may or may not provide a benefit. Our
data don’t prepare me to speak to the latter. However, to the
former, it’s our practice to aggressively manage these patients in
the perioperative period. We adopt a team approach with cardiol-
ogists and endocrinologists from the Joslin Diabetes Center, and
most all our patients have perioperative beta-blockade as well as
treatment with antiplatelet agents. We frequently use pulmonary
artery catheters, and all our patients recover in a specialized vascu-
lar nursing unit that has been cited for low mortality rates in the
past.
Finally, at present we do not have a uniform approach to
preoperative cardiac evaluation for patients undergoing infraingui-
nal reconstruction or aortic procedures.
Dr Jerry Goldstone (Cleveland, Ohio). I just wanted to
amplify a little bit, because the previous discussant asked, really, my
question regarding the anesthetic management. Was the anesthetic
management uniform across the groups, or was the management
of the patients who had had cardiac workup different from those
who did not?
We have found that the anesthetic management is integral to
the surgical management in our patients, and I think that may, in
some ways, explain some of your data. You’ve partially answered
the question already, but are there any other details about the
anesthetic that you can provide?
Dr Monahan. It is our practice to perform these procedures
under general anesthesia. Data from a prospective randomized trial
performed at our institution involving over four hundred patients
with invasive perioperative hemodynamic monitoring demon-
strated no difference in perioperative mortality or cardiac morbid-
ity in patients who had general, epidural, or spinal anesthesia.
Dr Richard Cambria (Boston, Mass). Nice job and an excel-
lent series with excellent results, although I would just caution a bit
in universally adopting your conclusion. Remember, firstly, that
the Eagle criteria and the Annals of Internal Medicine paper that
you showed from 1989 were developed in an era when event rates
were substantially higher than your excellent results. As a matter of
fact, in a previous report from our institution, the patient under-
going infrainguinal bypass surgery was the single highest risk group
for perioperative cardiac event rates. The evolution of events in this
group was often as high as fifteen percent. So your very low event
rate has an impact, obviously, on your results and conclusions.
And secondly, by the time you stratified your groups, you had
relatively small numbers; and a not unsubstantial percentage of
your workup group, in fact, did have a coronary intervention. So
the protective effect of that may explain the equivalent results in
the two groups. I think most vascular surgeons have come around
to the recognition that a patient with a pressing indication for
lower extremity revascularization ought to have that revasculariza-
tion with best medical management of their associated coronary
disease. But I would caution throwing out the whole concept of
cardiac evaluation in patients whose clinical profile clearly indicates
that they need it, irrespective of the timing of an operation.
Dr Monahan. I completely agree with your comments. Pa-
tients whose clinical profile clearly indicated that they needed a
cardiac evaluation were eliminated from our study group; any
patient with a major clinical predictor was not considered in this
study. Likewise patients undergoing emergent operation were not
considered. The patients in this study met inclusion criteria largely
because of their age and diabetes. The weight of these risk factors
as proposed by Dr Eagle is debated amongst cardiologists. We are
challenging the idea that age and diabetes alone should trigger a
preoperative cardiac evaluation.
Additionally, of the ten patients in the work-up group who
had preoperative coronary revascularization, there was one death
in a patient who had had an angioplasty, which occurred at
seventy-six days. The survival of these ten patients at one and two
years was ninety percent at both time points, which by Kaplan-
Meier analysis was not different from the two curves that I pre-
sented earlier. However, obviously, with only ten patients, there is
potential for significant type-two error.
INVITED COMMENTARY
Joseph L. Mills, Sr, MD, Tucson, Ariz
Coronary artery disease (CAD) commonly lurks in patients
with peripheral arterial disease (PAD), and the more severe the
PAD the worse the CAD. Patients with unstable coronary syn-
dromes, uncompensated congestive heart failure (CHF), uncon-
trolled arrhythmias, and severe valve disease (major predictors)
require cardiac evaluation, regardless of whether a peripheral inter-
vention is on the horizon. Absent major predictors, patients who
require infrainguinal bypass to treat limb-threatening ischemia still
constitute a group at high risk. The clinical conundrum remains: to
what extent does one evaluate cardiac risk in patients who require
infrainguinal bypass or, for that matter, any other peripheral arte-
rial reconstruction?
The Deaconess group, with longstanding expertise in limb
salvage surgery, takes issue with the “ACC/AHA Guideline on
Perioperative Cardiovascular Evaluation for Noncardiac Surgery.”
This document, based on expert, well-meaning opinion, but pre-
cious little hard evidence, suggests that all peripheral arterial oper-
ations are “high risk” and that at least preoperative noninvasive
cardiac testing is required in such patients in the presence of
intermediate predictors, such as mild angina pectoris, previous
myocardial infarction, previous or compensated CHF, renal insuf-
ficiency, or diabetes mellitus.
The authors report a retrospective, nonrandomized study of
140 patients with diabetes undergoing infrainguinal bypass. Car-
diac evaluation was performed at the discretion of the attending
surgeon: 79 patients receiving cardiac evaluation constituted the
workup group, and 61 patients underwent leg bypass with no
cardiac workup. There was no difference in postoperative cardiac
morbidity between the workup and no cardiac workup groups, and
patient survival at 1, 12, and 24 months was identical. The authors
conclude that mandatory preoperative cardiac evaluation, at least
in patients with diabetes who require leg bypass, is unnecessary.
There are problems with the study. It is subject to type II
errors because of small sample size and low event rate, and there is
likely selection bias, inasmuch as significantly more patients in the
workup group had a history of CAD, previous MI, or CHF.
Nevertheless, I suspect the authors are correct. Noninvasive car-
diac testing is flawed by low positive predictive value, and may lead
to unwarranted interventions, such as percutaneous transluminal
coronary angioplasty or coronary bypass, which have not been
scientifically demonstrated to reduce MI or cardiac mortality in
patients with PAD. There is, however, level I evidence that
-blockade is an effective strategy, even in patients at high-risk.1
I suspect that the era of routine preoperative cardiac testing is
at an end, because of its high cost and entirely unproved benefit on
outcomes. We should routinely prescribe -blockade, and perhaps
also statin agents and angiotensin converting enzyme inhibitors in
selected patients, and optimize medical management, and reserve
detailed cardiac testing for patients with major predictors that
warrant cardiac evaluation independent of the need for PAD
intervention.
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